# Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)

Study · id `cardio:ct-nct06353334` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06353334](<https://clinicaltrials.gov/study/NCT06353334>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06353334

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06353334. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06353334, source copy `cardio:ctgov-nct06353334-2025-02-07`, retrieved 2026-10-26)
- Started: 2021-09-01 (actual) (ClinicalTrials.gov record NCT06353334, source copy `cardio:ctgov-nct06353334-2025-02-07`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06353334, source copy `cardio:ctgov-nct06353334-2025-02-07`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06353334, source copy `cardio:ctgov-nct06353334-2025-02-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06353334, source copy `cardio:ctgov-nct06353334-2025-02-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06353334-2025-02-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)
- Condition: Butylphthalide
- Condition: Cardiac Arrest
- Condition: Neuroprotective Drugs
- Intervention (Drug): Butylphthalide and Sodium Chloride Injection
- Intervention (Drug): Saline Solution
- Lead sponsor: Tang Ziren
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)

## Provenance

Content hash: 69b3e0f84f26ebb018a5cf681f6cb7646775df16849c2c33c81d7f3f42f32bdb
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
